Inventor · disambiguated record
Eyal Breitbart
Also filed as: BREITBART EYAL
29 granted patents·29 pending applications·207 citations·filing 2002–2022
96Inventor score
Files withVASCULAR BIOGENICS LTD39HARATS DROR7COHEN YAEL4IMMUNEWALK THERAPEUTICS INC3BREITBART EYAL2
Top patents by PatentIndex Score
58 records- 0193US7989427B2Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapyVASCULAR BIOGENICS LTD·Filed 2008·Granted Aug 2, 2011·21 cites·6 claims
- 0292US8039261B2Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisVASCULAR BIOGENICS LTD·Filed 2006·Granted Oct 18, 2011·27 cites·39 claims
- 0391US11697682B2Motile sperm domain containing protein 2 antibodies and methods of use thereofVASCULAR BIOGENICS LTD·Filed 2021·Granted Jul 11, 2023·2 cites·29 claims
- 0491US8415318B2Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapyHARATS DROR·Filed 2011·Granted Apr 9, 2013·14 cites·26 claims
- 0591US8206743B2Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisHARATS DROR·Filed 2011·Granted Jun 26, 2012·14 cites·26 claims
- 0690US7585666B2Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapyVASCULAR BIOGENICS LTD·Filed 2002·Granted Sep 8, 2009·29 cites·5 claims
- 0789US10383954B2Methods of inducing responsiveness to anti-angiogenic agentVASCULAR BIOGENICS LTD·Filed 2017·Granted Aug 20, 2019·4 cites·18 claims
- 0888US7579327B2Promoters exhibiting endothelial cell specificity and methods of using sameVASCULAR BIOGENICS LTD·Filed 2004·Granted Aug 25, 2009·23 cites·10 claims
- 0987US9682154B2Methods of inducing responsiveness to anti-angiogenic agentVASCULAR BIOGENICS LTD·Filed 2014·Granted Jun 20, 2017·6 cites·20 claims
- 1087US8071740B2Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisHARATS DROR·Filed 2004·Granted Dec 6, 2011·19 cites·21 claims
- 1185US8835398B2Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisHARATS DROR·Filed 2012·Granted Sep 16, 2014·6 cites·35 claims
- 1284US8859745B2Promoters exhibiting endothelial cell specificity and methods of using sameHARATS DROR·Filed 2009·Granted Oct 14, 2014·5 cites·32 claims
- 1384US8859747B2Promoters exhibiting endothelial cell specificity and methods of using sameVASCULAR BIOGENICS LTD·Filed 2013·Granted Oct 14, 2014·5 cites·31 claims
- 1484US8846401B2Promoters exhibiting endothelial cell specificity and methods of using sameHARATS DROR·Filed 2012·Granted Sep 30, 2014·5 cites·34 claims
- 1583US8916378B2Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapyVASCULAR BIOGENICS LTD·Filed 2013·Granted Dec 23, 2014·4 cites·20 claims
- 1682US11191848B2Methods of inducing responsiveness to anti-angiogenic agentVASCULAR BIOGENICS LTD·Filed 2019·Granted Dec 7, 2021·1 cites·16 claims
- 1781US11311583B2Treatment methods using adenovirusVASCULAR BIOGENICS LTD·Filed 2018·Granted Apr 26, 2022·1 cites·11 claims
- 1881US9771385B2Oxidized lipidsVASCULAR BIOGENICS LTD·Filed 2015·Granted Sep 26, 2017·2 cites·37 claims
- 1979US9567605B2Methods for use of a specific anti-angiogenic adenoviral agentCOHEN YAEL·Filed 2011·Granted Feb 14, 2017·4 cites·26 claims
- 2078US9200056B2FAS-chimera adenovirus vectorVASCULAR BIOGENICS LTD·Filed 2014·Granted Dec 1, 2015·3 cites·23 claims
- 2177US11945875B2Motile sperm domain containing protein 2 and cancerIMMUNEWALK THERAPEUTICS INC·Filed 2020·Granted Apr 2, 2024·1 cites·17 claims
- 2277US10022388B2Oxidized lipids and treatment or prevention of fibrosisVASCULAR BIOGENICS LTD·Filed 2017·Granted Jul 17, 2018·2 cites·19 claims
- 2376US9206206B2Oxidized lipid compounds and uses thereofKOVALEVSKI-ISHAI ETI·Filed 2009·Granted Dec 8, 2015·5 cites·28 claims
- 2474US8999960B2Oxidized thiophospholipid compounds and uses thereofBREITBART EYAL·Filed 2009·Granted Apr 7, 2015·4 cites·35 claims
- 2571US2022331383A1Treatment methods using adenovirusVASCULAR BIOGENICS LTD·Filed 2022·Application pending·0 cites
- 2668US2010081193A1Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisVASCULAR BIOGENICS LTD·Filed 2009·Application pending·0 cites
- 2760US2011230450A1Platelet-activating factor (paf) analogs and uses thereofVascular Biogenics Lts·Filed 2008·Application pending·0 cites
- 2860US2013280217A1Methods for Use of a Specific Anti-Angiogenic Adenoviral AgentVASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 2960US2013280216A1Methods for Use of a Specific Anti-Angiogenic Adenoviral AgentVASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 3058US2010298226A1Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemiaVASCULAR BIOGENICS LTD·Filed 2007·Application pending·0 cites
- 3157US9403887B2Endothelial cell-specific polynucleotides and use thereofVASCULAR BIOGENICS LTD·Filed 2014·Granted Aug 2, 2016·0 cites·23 claims
- 3255US12109264B2Motile sperm domain containing protein 2 and inflammationIMMUNEWALK THERAPEUTICS INC·Filed 2020·Granted Oct 8, 2024·0 cites·20 claims
- 3355US2013225525A1Combined Treatment Utilizing VB-201VASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 3455US2011201677A1Promoters exhibiting endothelial cell specificity and methods of using sameVASCULAR BIOGENICS LTD·Filed 2011·Application pending·0 cites
- 3555US2011207985A1Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisVASCULAR BIOGENICS LTD·Filed 2011·Application pending·0 cites
- 3654US2025277052A1Motile sperm domain containing protein 2, integrin beta2 and cd63IMMUNEWALK THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3753US2013295053A1Methods of Producing Adenovirus Vectors and Viral Preparations Generated TherebyVASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 3851US10206936B2Oxidized lipids and treatment or prevention of fibrosisVASCULAR BIOGENICS LTD·Filed 2018·Granted Feb 19, 2019·0 cites·22 claims
- 3951US2016143968A1Treatment methods using adenovirusVASCULAR BIOGENICS LTD·Filed 2015·Application pending·0 cites
- 4051US2022185891A1Methods of anti-tumor therapyVASCULAR BIOGENICS LTD·Filed 2020·Application pending·0 cites
- 4151US2014155467A1Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesisVASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 4248US10369196B2Compositions and methods for treating glioblastoma GBMVASCULAR BIOGENICS LTD·Filed 2013·Granted Aug 6, 2019·0 cites·17 claims
- 4348US2013203707A1Oxidized Lipid Compounds and Uses ThereofVASCULAR BIOGENICS LTD·Filed 2013·Application pending·0 cites
- 4448US2010282634A1Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of AngiogenesisHARATS DROR·Filed 2007·Application pending·0 cites
- 4547US10464957B2Oxidized lipids and methods of use thereofVASCULAR BIOGENICS LTD·Filed 2017·Granted Nov 5, 2019·0 cites·27 claims
- 4647US2016008381A1Combined Treatment Utilizing VB-201VASCULAR BIOGENICS LTD·Filed 2015·Application pending·0 cites
- 4746US2013052165A1Methods of Producing Adenovirus Vectors and Viral Preparations Generated TherebyBANGIO LIVNAT·Filed 2011·Application pending·0 cites
- 4846US2013172294A1Treatment with VB-201COHEN YAEL·Filed 2011·Application pending·0 cites
- 4946US2021322574A1Diagnostic methods for anti-angiogenic agent therapyVASCULAR BIOGENICS LTD·Filed 2018·Application pending·0 cites
- 5046US2020407434A1Bispecific antibodies to mospd2 and t cell- or nk cell-specific moleculesVASCULAR BIOGENICS LTD·Filed 2019·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Eyal Breitbart files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →